Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus

Hepatology

Volumn 42, Issue 5, 2005, Pages 1046-1054

  Tsuge, Masataka ^a,b   Hiraga, Nobuhiko ^a,b   Takaishi, Hideki ^a,b   Noguchi, Chiemi ^a,b   Oga, Hiromi ^a,b   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Iwao, Eiji ^c   Fujimoto, Yoshifumi ^b,d   Ochi, Hidenori ^b,d   Chayama, Kazuaki ^a,b,d   Tateno, Chise ^b,e   Yoshizato, Katsutoshi ^b,e  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^e Hiroshima Prefectural Institute of Industrial Science and Technology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL KILLING; CELL STRAIN HEPG2; CHIMERA; CLONE; CONTROLLED STUDY; DNA MODIFICATION; DNA TRANSFECTION; DRUG EFFICACY; GENETIC ENGINEERING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIREMIA; VIROGENESIS; VIRUS MUTANT; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CELL LINE, TUMOR; CHIMERA; DNA, VIRAL; GENETIC ENGINEERING; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HISTOCYTOCHEMISTRY; HUMANS; LAMIVUDINE; LIVER; MICE; MUTATION; TIME FACTORS; VIREMIA;

EID: 30944468404     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20892     Document Type: Article

References (31)

1. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;27;342:1340-1344.
2. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2003;39 Suppl 1:S59-S63.
3. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol 2003;39(Suppl 1):S26-S30.
4. Ganem D, Prince A. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
5. Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004;318:134-141.
6. Gagneux P, Muchmore EA. The chimpanzee model: contributions and considerations for studies of hepatitis B virus. Methods Mol Med 2004;96:289-318.
7. Muchmore EA. Chimpanzee models for human disease and immunobiology. Immunol Rev 2001;183:86-93.
8. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. HEPATOLOGY 2004;39:1469-1475.
9. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995;69:6158-6169.
10. Uprichard SL, Wieland SF, Althage A, Chisari FV. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A. 2003;100:1310-1315.
11. Nakamoto Y, Suda T, Momoi T, Kaneko S. Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 2004;64:3326-3333.
12. Iyer RP, Roland A, Jin Y, Mounir S, Korba B, Julander JG, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004;48:2318-2320.
13. Ilan E, Burakova T, Dagan S, Nussbaum O, Ido L, Eren R, et al. The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. HEPATOLOGY 1999;29:553-562.
14. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. HEPATOLOGY 2001;33:981-988.
15. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. HEPATOLOGY 2000;31:173-181.
16. Petersen J, Dandri M, Gupta S, Rogler CE. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1998;95:310-315.
17. Dandri M, Burda MR, Zuckerman DM, Wursthorn K, Matschl U, Pollok JM, et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 2005;42:54-60.
18. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001;7:927-933.
19. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-912.
20. Gunther S, Sommer G, Von Breunig F, Iwanska A, Kalinina T, Sterneck M, et al. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol 1998,36:531-538.
21. Kim HY, Park GS, Kim EG, Kang SH, Shin HJ, Park S, et al. Oligomer synthesis by priming deficient polymerase in hepatitis B virus core particle. Virology 2004;322:22-30.
22. Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H, et al. Cloned HBV DNA causes hepatitis in chimpanzees. Nature 1982;299:740-742.
23. Gagneux P, Muchmore EA. The chimpanzee model: contributions and considerations for studies of hepatitis B virus. Methods Mol Med 2004;96:289-318.
24. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. HEPATOLOGY 2005;41:847-856.
25. Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993;194:263-276.
26. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;2:103-106.
27. Dienstag JE, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;25:1657-1661.
28. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
29. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;3:714-717.
30. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 1997;26:1393-1395.
31. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. HEPATOLOGY 1998;27:1711-1716.